Wolf Rogowski

Wolf Rogowski

Auto-generated profile, based on publicly available information

Wolf Rogowski

Department of Health Care Management, Institute of Public Health and Nursing Research, Health Sciences, University of Bremen, Bremen, Germany

Research Focus & Metrics

Academic Career Length

21Years (2006-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
21 December 2013 in BMC Medical Ethics
Verified
Journal Article
Open access
PDF file
SSSebastian Schleidgen
Sebastian Schleidgen
CKCorinna Klingler
Corinna Klingler
TBTeresa Bertram
Teresa Bertram
WRWolf H Rogowski
Wolf H Rogowski
GMGeorg Marckmann
Georg Marckmann
Recently, individualized or personalized medicine (PM) has become a buzz word in the academic as well as public debate surrounding health care. However, PM lacks a clear definition and is open to interpretation. This conceptual vagueness complicates public discourse on chances, risks and limits of PM. Furthermore, stakeholders might use it to further their respective interests and preferences. For these reasons it is important to have a shared understanding of PM. In this paper, we present a sufficiently precise as well as adequate definition of PM with the potential of wide acceptance.

10 July 2009 in BMC Health Services Research
Verified
Journal Article
Open access
PDF file
ALAstrid Langer
Astrid Langer
WRWolf Rogowski
Wolf Rogowski
Tissue engineering is an emerging field. Novel bioengineered skin substitutes and genetically derived growth factors offer innovative approaches to reduce the burden of diabetic foot and venous leg ulcers for both patients and health care systems. However, they frequently are very costly. Based on a systematic review of the literature, this study assesses the cost-effectiveness of these growth factors and tissue-engineered artificial skin for treating chronic wounds.

18 January 2018 in Diabetes Care
Verified
Journal Article
Open access
PDF file
KKKatharina Kähm
Katharina Kähm
MLMichael Laxy
Michael Laxy
USUdo Schneider
Udo Schneider
WRWolf H. Rogowski
Wolf H. Rogowski
Stefan LhachimiStefan Lhachimi
Stefan Lhachimi
RHRolf Holle
Rolf Holle
OBJECTIVE: The aim of this study is to provide reliable regression-based estimates of costs associated with different type 2 diabetes complications. RESEARCH DESIGN AND METHODS: We used nationwide statutory health insurance (SHI) data from 316,220 patients with type 2 diabetes. Costs for inpatient and outpatient care, pharmaceuticals, rehabilitation, and nonmedical aids and appliances were assessed in the years 2013–2015. Quarterly observations are available for each year. We estimated costs (in 2015 euro) for complications using a generalized estimating equations model with a normal distribution adjusted for age, sex, occurrence of different complications, and history of complications at baseline, 2012. Two- and threefold interactions were included in an extended model. RESULTS: The base case model estimated total costs in the quarter of event for the example of a 60- to 69-year-old man as follows: diabetic foot €1,293, amputation €14,284, retinopathy €671, blindness €2,933, nephropathy €3,353, end-stage renal disease (ESRD) €22,691, nonfatal stroke €9,769, fatal stroke €11,176, nonfatal myocardial infarction (MI)/cardiac arrest (CA) €8,035, fatal MI/CA €8,700, nonfatal ischemic heart disease (IHD) €6,548, fatal IHD €20,942, chronic heart failure €3,912, and angina pectoris €2,695. In the subsequent quarters, costs ranged from €681 for retinopathy to €6,130 for ESRD. CONCLUSIONS: Type 2 diabetes complications have a significant impact on total health care costs in the SHI system, not only in the quarter of event but also in subsequent years. Men and women from different age-groups differ in their costs for complications. Our comprehensive estimates may support the parametrization of diabetes models and help clinicians and policy makers to quantify the economic burden of diabetes complications in the context of new prevention and treatment programs.

29 June 2009 in Public Health Genomics
Verified
Journal Article
Closed access
SGScott Grosse
Scott Grosse
WRW.H. Rogowski
W.H. Rogowski
LRL.F. Ross
L.F. Ross
MCM.C. Cornel
M.C. Cornel
WDW.J. Dondorp
W.J. Dondorp
MKM.J. Khoury
M.J. Khoury
Background: Proposals for population screening for genetic diseases require careful scrutiny by decision makers because of the potential for harms and the need to demonstrate benefits commensurate with the opportunity cost of resources expended. Methods: We review current evidence-based processes used in the United States, the United Kingdom, and the Netherlands to assess genetic screening programs, including newborn screening programs, carrier screening, and organized cascade testing of relatives of patients with genetic syndromes. In particular, we address critical evidentiary, economic, and ethical issues that arise in the appraisal of screening tests offered to the population. Specific case studies include newborn screening for congenital adrenal hyperplasia and cystic fibrosis and adult screening for hereditary hemochromatosis. Results: Organizations and countries often reach different conclusions about the suitability of screening tests for implementation on a population basis. Deciding when and how to introduce pilot screening programs is challenging. In certain cases, e.g., hereditary hemochromatosis, a consensus does not support general screening although cascade screening may be cost-effective. Conclusion: Genetic screening policies have often been determined by technological capability, advocacy, and medical opinion rather than through a rigorous evidence-based review process. Decision making should take into account principles of ethics and opportunity costs.

1 July 2009 in Nature Reviews Genetics
Verified
Journal Article
Closed access
WRWolf H. Rogowski
Wolf H. Rogowski
SGScott Grosse
Scott Grosse
MKMuin J. Khoury
Muin J. Khoury

17 March 2011 in European Journal of Human Genetics
Verified
Journal Article
Closed access
PDF file
FBFrauke Becker
Frauke Becker
CECarla G van El
Carla G van El
DIDolores Ibarreta
Dolores Ibarreta
EZEleni Zika
Eleni Zika
SHStuart Hogarth
Stuart Hogarth
Martina C CornelMartina C Cornel
Martina C Cornel